Cargando…
A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685397/ https://www.ncbi.nlm.nih.gov/pubmed/37967346 http://dx.doi.org/10.1093/europace/euad320 |
_version_ | 1785151621897912320 |
---|---|
author | Jonmundsson, Thorarinn Steindorsdottir, Anna E Austin, Thomas R Frick, Elisabet A Axelsson, Gisli T Launer, Lenore Psaty, Bruce M Loureiro, Joseph Orth, Anthony P Aspelund, Thor Emilsson, Valur Floyd, James S Jennings, Lori Gudnason, Vilmundur Gudmundsdottir, Valborg |
author_facet | Jonmundsson, Thorarinn Steindorsdottir, Anna E Austin, Thomas R Frick, Elisabet A Axelsson, Gisli T Launer, Lenore Psaty, Bruce M Loureiro, Joseph Orth, Anthony P Aspelund, Thor Emilsson, Valur Floyd, James S Jennings, Lori Gudnason, Vilmundur Gudmundsdottir, Valborg |
author_sort | Jonmundsson, Thorarinn |
collection | PubMed |
description | AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study. METHODS AND RESULTS: The study included 4765 participants, of whom 1172 developed AF. Cox proportional hazards regression models were fitted for 4137 baseline protein measurements adjusting for known risk factors. Protein associations were tested for replication in the Cardiovascular Health Study (CHS). Causal relationships were examined in a bidirectional, two-sample Mendelian randomization analysis. The time-dependent area under the receiver operating characteristic curve (AUC)-statistic was examined as protein levels and an AF-polygenic risk score (PRS) were added to clinical risk models. The proteomic signature of incident AF consisted of 76 proteins, of which 63 (83%) were novel and 29 (38%) were replicated in CHS. The signature included both N-terminal prohormone of brain natriuretic peptide (NT-proBNP)-dependent (e.g. CHST15, ATP1B1, and SVEP1) and independent components (e.g. ASPN, AKR1B, and LAMA1/LAMB1/LAMC1). Nine causal candidates were identified (TAGLN, WARS, CHST15, CHMP3, COL15A1, DUSP13, MANBA, QSOX2, and SRL). The reverse causal analysis suggested that most AF-associated proteins were affected by the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide improved the prediction of incident AF events close to baseline with further improvements gained by the AF-PRS at all time points. CONCLUSION: The AF proteomic signature includes biologically relevant proteins, some of which may be causal. It mainly reflects an NT-proBNP-dependent consequence of the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide is a promising marker for incident AF in the short term, but risk assessment incorporating a PRS may improve long-term risk assessment. |
format | Online Article Text |
id | pubmed-10685397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106853972023-11-30 A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) Jonmundsson, Thorarinn Steindorsdottir, Anna E Austin, Thomas R Frick, Elisabet A Axelsson, Gisli T Launer, Lenore Psaty, Bruce M Loureiro, Joseph Orth, Anthony P Aspelund, Thor Emilsson, Valur Floyd, James S Jennings, Lori Gudnason, Vilmundur Gudmundsdottir, Valborg Europace Translational Research AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study. METHODS AND RESULTS: The study included 4765 participants, of whom 1172 developed AF. Cox proportional hazards regression models were fitted for 4137 baseline protein measurements adjusting for known risk factors. Protein associations were tested for replication in the Cardiovascular Health Study (CHS). Causal relationships were examined in a bidirectional, two-sample Mendelian randomization analysis. The time-dependent area under the receiver operating characteristic curve (AUC)-statistic was examined as protein levels and an AF-polygenic risk score (PRS) were added to clinical risk models. The proteomic signature of incident AF consisted of 76 proteins, of which 63 (83%) were novel and 29 (38%) were replicated in CHS. The signature included both N-terminal prohormone of brain natriuretic peptide (NT-proBNP)-dependent (e.g. CHST15, ATP1B1, and SVEP1) and independent components (e.g. ASPN, AKR1B, and LAMA1/LAMB1/LAMC1). Nine causal candidates were identified (TAGLN, WARS, CHST15, CHMP3, COL15A1, DUSP13, MANBA, QSOX2, and SRL). The reverse causal analysis suggested that most AF-associated proteins were affected by the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide improved the prediction of incident AF events close to baseline with further improvements gained by the AF-PRS at all time points. CONCLUSION: The AF proteomic signature includes biologically relevant proteins, some of which may be causal. It mainly reflects an NT-proBNP-dependent consequence of the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide is a promising marker for incident AF in the short term, but risk assessment incorporating a PRS may improve long-term risk assessment. Oxford University Press 2023-11-15 /pmc/articles/PMC10685397/ /pubmed/37967346 http://dx.doi.org/10.1093/europace/euad320 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Translational Research Jonmundsson, Thorarinn Steindorsdottir, Anna E Austin, Thomas R Frick, Elisabet A Axelsson, Gisli T Launer, Lenore Psaty, Bruce M Loureiro, Joseph Orth, Anthony P Aspelund, Thor Emilsson, Valur Floyd, James S Jennings, Lori Gudnason, Vilmundur Gudmundsdottir, Valborg A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title | A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title_full | A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title_fullStr | A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title_full_unstemmed | A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title_short | A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) |
title_sort | proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (ages-reykjavik study) |
topic | Translational Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685397/ https://www.ncbi.nlm.nih.gov/pubmed/37967346 http://dx.doi.org/10.1093/europace/euad320 |
work_keys_str_mv | AT jonmundssonthorarinn aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT steindorsdottirannae aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT austinthomasr aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT frickelisabeta aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT axelssongislit aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT launerlenore aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT psatybrucem aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT loureirojoseph aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT orthanthonyp aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT aspelundthor aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT emilssonvalur aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT floydjamess aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT jenningslori aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT gudnasonvilmundur aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT gudmundsdottirvalborg aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT jonmundssonthorarinn proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT steindorsdottirannae proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT austinthomasr proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT frickelisabeta proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT axelssongislit proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT launerlenore proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT psatybrucem proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT loureirojoseph proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT orthanthonyp proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT aspelundthor proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT emilssonvalur proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT floydjamess proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT jenningslori proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT gudnasonvilmundur proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy AT gudmundsdottirvalborg proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy |